Cardinal Health, Inc.’s CAH Specialty Solutions recently introduced Cardinal Health Navista Tech Solutions (TS), which is an advanced suite of technology solutions. The latest launch will enable community oncologists to boost patient outcomes and lower costs with respect to their treatment while they shift to value-based care.
This announcement is likely to bolster Cardinal Health’s Pharmaceutical segment.
Benefits of Navista TS
It is worth mentioning that community-based oncology practices have been under immense pressure as they turn to value-based reimbursement models, while continuing to offer superior quality of care.
Being the only fully integrated resource for value-based care decisions, Navita TS can aid oncology practices become successful by balancing clinical and financial decision-making in a single place on the back of connected tools and data-driven insights. This, in turn, will allow oncologists to enhance patient care and practice performance.
This all-inclusive suite of solutions not only helps to automate manual processes but also lowers administrative burdens. This innovative suite aids oncology practices to understand the highest cost and value drivers, detect treatments that are cheapest while providing the most superior quality of care and choose the correct care plan at the beginning of treatment.
Per a report by The Business Research Company, the global value based care payment market is anticipated to grow from $1.52 billion in 2020 to $2.27 billion in 2021 at a CAGR of 49.5%. Notably, the market is projected to reach $4.03 billion in 2025 at a CAGR of 15%.
Hence, the launch is well-timed for Cardinal Health.
Another Notable Development
In January 2021, Cardinal Health’s company, OptiFreight Logistics, introduced TotalVue Analytics, which is a tool that will enable healthcare supply chain leaders to use predictive technology and data to detect logistics savings and benchmarking. Notably, this solution will help customers by offering them actionable data.
Shares of this Zacks Rank #3 (Hold) company have gained 10.6% on a year-to-date basis, compared with the industry’s growth of 4.4%.
Stocks to Consider
Some better-ranked stocks from the broader medical space are Hologic, Inc. HOLX, Hill-Rom Holdings, Inc. HRC and Cantel Medical Corp. CMD, each currently carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Hologic’s long-term earnings growth rate is expected at 15.4%.
Hill-Rom Holdings’ long-term earnings growth rate is estimated at 7.3%.
Cantel Medical’s long-term earnings growth rate is estimated at 19%.
Zacks Names “Single Best Pick to Double”
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
You know this company from its past glory days, but few would expect that it’s poised for a monster turnaround. Fresh from a successful repositioning and flush with A-list celeb endorsements, it could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in a little more than 9 months and Nvidia which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report